459 related articles for article (PubMed ID: 32174754)
1. Immunotherapy in soft-tissue sarcoma.
Ayodele O; Razak ARA
Curr Oncol; 2020 Feb; 27(Suppl 1):17-23. PubMed ID: 32174754
[TBL] [Abstract][Full Text] [Related]
2. Potential for immunotherapy in soft tissue sarcoma.
Tseng WW; Somaiah N; Engleman EG
Hum Vaccin Immunother; 2014; 10(11):3117-24. PubMed ID: 25625925
[TBL] [Abstract][Full Text] [Related]
3. Next frontiers in systemic therapy for soft tissue sarcoma.
Yen CC; Chen TW
Chin Clin Oncol; 2018 Aug; 7(4):43. PubMed ID: 30173533
[TBL] [Abstract][Full Text] [Related]
4. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook.
Banks LB; D'Angelo SP
J Natl Compr Canc Netw; 2022 Jul; 20(7):834-844. PubMed ID: 35830892
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy and Biomarkers in Sarcoma.
Dajsakdipon T; Siripoon T; Ngamphaiboon N; Ativitavas T; Dejthevaporn T
Curr Treat Options Oncol; 2022 Mar; 23(3):415-438. PubMed ID: 35262852
[TBL] [Abstract][Full Text] [Related]
6. Soft tissue sarcoma as a model disease to examine cancer immunotherapy.
Maki RG
Curr Opin Oncol; 2001 Jul; 13(4):270-4. PubMed ID: 11429485
[TBL] [Abstract][Full Text] [Related]
7. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.
Frezza AM; Stacchiotti S; Gronchi A
BMC Med; 2017 Jun; 15(1):109. PubMed ID: 28571564
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Sarcoma: Where Do Things Stand?
Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A
Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
11. Emerging Targeted and Immune-Based Therapies in Sarcoma.
Pollack SM; Ingham M; Spraker MB; Schwartz GK
J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
13. Role of Virus-Directed Therapy in Soft Tissue Sarcoma.
Chaudhary H; D'Angelo S
Curr Treat Options Oncol; 2022 Mar; 23(3):404-414. PubMed ID: 35258792
[TBL] [Abstract][Full Text] [Related]
14. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.
Tang F; Tie Y; Wei YQ; Tu CQ; Wei XW
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188606. PubMed ID: 34371128
[TBL] [Abstract][Full Text] [Related]
15. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.
Wisdom AJ; Mowery YM; Riedel RF; Kirsch DG
Cancer; 2018 Oct; 124(19):3819-3829. PubMed ID: 29723407
[TBL] [Abstract][Full Text] [Related]
16. Exploring the landscape of immunotherapy approaches in sarcomas.
Pilavaki P; Panagi M; Arifi S; Jones RL; Stylianopoulos T; Constantinidou A
Front Oncol; 2022; 12():1069963. PubMed ID: 36686827
[TBL] [Abstract][Full Text] [Related]
17. Future directions in soft tissue sarcoma treatment.
Hall F; Villalobos V; Wilky B
Curr Probl Cancer; 2019 Aug; 43(4):300-307. PubMed ID: 31229264
[TBL] [Abstract][Full Text] [Related]
18. Current status of immunotherapy for sarcomas.
Miwa S; Nishida H; Tsuchiya H
Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of immunotherapy for the treatment of sarcoma.
Klemen ND; Kelly CM; Bartlett EK
J Surg Oncol; 2021 Mar; 123(3):730-738. PubMed ID: 33259653
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.
Groisberg R; Hong DS; Behrang A; Hess K; Janku F; Piha-Paul S; Naing A; Fu S; Benjamin R; Patel S; Somaiah N; Conley A; Meric-Bernstam F; Subbiah V
J Immunother Cancer; 2017 Dec; 5(1):100. PubMed ID: 29254498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]